Real‐world treatment burden of brentuximab vedotin‐based front‐line regimens in young adults and adults with advanced‐stage classical Hodgkin lymphoma
Real-world treatment burden of brentuximab vedotin-based frontline regimens in young adults and adults with advanced-stage classical Hodgkin lymphomaTo the Editor, We read with great enthusiasm the multicentre, retrospective study by Porges et al. in British Journal of Haematology in August 2026, 1 assessing front-line brentuximab vedotin, etoposide, cyclophosphamide, doxorubicin, dacarbazine, dexamethasone (BrECADD) in 100 advanced-stage classical Hodgkin lymphoma (cHL) patients (median age, 30 years).The outstanding disease control reported by the
Authors
- Annamaria Vincenzi (ORCID: https://orcid.org/0009-0003-5975-9388)
- Sara Pellegrino (ORCID: https://orcid.org/0000-0002-2325-3583)
- Claudia Giordano (ORCID: https://orcid.org/0000-0003-3943-4263)
- Fabrizio Pane (ORCID: https://orcid.org/0000-0003-2563-4125)
- Marco Picardi (ORCID: https://orcid.org/0000-0001-8508-2524)
- Novella Pugliese (ORCID: https://orcid.org/0000-0002-2714-5109)
Institutions
- Federico II University Hospital (IT)
- University of Naples Federico II (IT)
Publication Details
- Journal
- British Journal of Haematology
- Published
- 2026-11-18
- DOI
- https://doi.org/10.1111/bjh.70951
- Primary Topic
- Lymphoma Diagnosis and Treatment
- Type
- article
- Field-Weighted Citation Impact
- 0.00